Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

823518

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps are being taken to ensure that the UK enters the top quartile of comparator countries for the speed of adoption and overall uptake of innovative treatments as recommended in the Life Sciences Industrial Strategy.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	122988
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>Comparisons of uptake of medicines between different countries with different health systems are difficult and should be treated with caution. However, we are committed to working with industry on this issue and share the ambition to maximise the appropriate use of innovation in our system and tackle unwarranted variation in uptake. The Government and industry are currently working together through a series of workshops that will provide the foundation for the next medicines pricing scheme, and discussions around uptake, adoption and metrics have been a feature of those early meetings.</p><p> </p><p>The recent Government and partner bodies response to the Accelerated Access Review sets out how we will work with industry and the health system to create a streamlined and sophisticated approvals system so that cost-effective breakthrough products – be they drugs, devices, digital or diagnostics – can get into the National Health Service as fast as possible.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 11:57:48 answering member 4067 label Biography information for Steve Brine
tabling member	104 label Biography information for Crispin Blunt

823522

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps are being taken to update and evolve value assessments of drugs, medical devices and diagnostics, as recommended in the Life Sciences Industrial Strategy.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	122991
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is committed to playing its part in delivering the vision set out in the Life Sciences Industrial Strategy. Ensuring that appraisals are fit for purpose in a fast-changing sector is critical. NICE has recently taken steps to do this by introducing changes to its processes to support faster access to the most effective treatments, while addressing affordability issues. In addition, NICE has recently consulted on further changes to streamline its technology appraisal processes so that it is better able to develop new guidance on innovative drugs and medical technologies.</p><p> </p><p>As set out in the response to the Accelerated Access Review, we are also introducing a new Accelerated Access Pathway, to streamline regulatory and market access decisions for a small number of products, getting breakthrough products that we believe will be truly transformative to patients even more quickly.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 16:38:26 answering member 4067 label Biography information for Steve Brine
tabling member	104 label Biography information for Crispin Blunt

823523

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the extension of Orkambi's licence to treat patients aged six and over, what support his Department is giving to further negotiations among NICE, NHS England and the drug manufacturer, Vertex, on access to that medicine for people with cystic fibrosis.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	122992
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>The Department wants patients with cystic fibrosis to benefit from clinically and cost effective treatments, and we welcome the on-going dialogue between Vertex and NHS England to pursue a deal that would make Orkambi available to National Health Service patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 12:13:27 answering member 4067 label Biography information for Steve Brine
tabling member	104 label Biography information for Crispin Blunt